Health Care [ 4/12 ] | Biotechnology [ 32/74 ]
NASDAQ | Common Stock
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies.
The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.
Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus.
Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 31, 24 | -0.04 Increased by +80.95% | -0.31 Increased by +87.10% |
| Aug 14, 24 | -0.12 Increased by +42.86% | -0.39 Increased by +69.23% |
| May 28, 24 | 0.30 Increased by +225.00% | -0.56 Increased by +153.57% |
| Mar 26, 24 | -1.60 Increased by +44.83% | -1.60 |
| Dec 19, 23 | -0.21 Increased by +12.50% | -0.19 Decreased by -10.53% |
| Aug 18, 23 | -0.21 Decreased by -5.00% | -0.21 |
| May 31, 23 | -0.24 Increased by +4.00% | -0.24 |
| Dec 31, 22 | -2.90 Decreased by -643.59% | -2.63 Decreased by -10.27% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 3.03 M Increased by +N/A% | -1.94 M Increased by +65.81% | Decreased by -64.14% Decreased by N/A% |
| Jun 30, 24 | 153.89 K Increased by +N/A% | -6.19 M Decreased by -9.08% | Decreased by -4.02 K% Decreased by N/A% |
| Mar 31, 24 | 50.88 K Increased by +N/A% | 1.19 M Increased by +117.37% | Increased by +2.35 K% Decreased by N/A% |
| Dec 31, 23 | 73.60 K Increased by +N/A% | -4.56 M Increased by +33.64% | Decreased by -6.20 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -5.68 M Increased by +1.08% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -5.68 M Decreased by -19.09% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -6.87 M Decreased by -18.67% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -6.87 M Increased by +17.90% | Decreased by N/A% Decreased by N/A% |